Tyrosine Kinase Inhibitors: all 10,469 studies that test it

Page 60 of 105. Open to participants first (1,907), then studies with results posted, then the rest; newest registration first within each.

• Anlotinib Combined With Platinum/Gemcitabine for First Line Treatment of Advanced Urothelial CarcinomaStatus unknownNCT05030077Phase 2
• Phase III Study on HMPL-523 for Treatment of ITPCompletedNCT05029635Phase 3
• Apatinib Combined With Chemotherapy Versus Chemotherapy in Second-line Gastric Cancer Receiving Prior Anti-PD-1 TherapyStatus unknownNCT05029453Phase 4
• Apatinib Mesylate Combined With IT Regimen for the Treatment of Recurrent or Refractory Neuroblastoma: A Single-arm, Phase I/II，Multi-center, Clinical Study.CompletedNCT05027386Phase 1/2
• A Phase II Study on Dose Optimization of Fruquintinib in Elderly mCRC Patients Refractory to Standard Treatment（DOFEMCRC）CompletedNCT05025631Phase 2
• A Study of TKI Maintenance Therapy Following Allo-HSCT in Newly Diagnosed Ph+ Adult ALLStatus unknownNCT05024357Not applicable
• Public Health Emergency: SOLIDARITY TRIAL PhilippinesCompletedNCT05024006Not applicable
• Orelabrutinib in Combination With Thiotepa in Refractory and Relapsed Primary CNS LymphomaStatus unknownNCT05021770Phase 1/2
• Toripalimab Combined With Anlotinib and SBRT in Patients With Untreated Brain Metastases of Driven Gene-negative NSCLCCompletedNCT05021328Phase 1
• Basiliximab Combined With Ruxolitinib as Second-line Treatment of Grade 3-4 Steroid-resistant aGVHDStatus unknownNCT05021276Phase 4
• Screening Plasma HER2 Amplication by Digital PCR in Advanced Breast Cancer Patients Treated With Trastuzumab and PyrotinibStatus unknownNCT05020964Phase 2
• SI-B001 Combined With Osimertinib Mesylate Tablets in the Treatment of Recurrent Metastatic Non-small Cell Lung Cancer.Active, not recruitingNCT05020769Phase 2/3
• A Clinical Trial of TQ05105 Tablets in the Treatment of Moderate and High Risk MyelofibrosisCompletedNCT05020652Phase 2
• A Clinical Trial of the Orelabrutinib in the Management of Refractory ITPStatus unknownNCT05020288Phase 2
• Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR AlterationsStatus unknownNCT05019794Phase 2
• Aurora Kinase Inhibitor LY3295668 in Combination With Osimertinib for the Treatment of Advanced or Metastatic EGFR-Mutant Non-squamous Non-small Cell Lung CancerCompletedNCT05017025Phase 1/2
• Fruquintinib Plus Capecitabine as Maintenance Treatment of RAS / BRAF Wild-type Metastatic Colorectal CancerStatus unknownNCT05016869Phase 1/2
• Efficacy and Safety of Baricitinib in Sjogren's SyndromeCompletedNCT05016297Phase 2
• Study on Savolitinib Combined With Osimertinib in Treatment of Advanced NSCLC With MET AmplificationCompletedNCT05015608Phase 3
• Alectinib in Neo-adjuvant Treatment of Stage III NSCLCActive, not recruitingNCT05015010Phase 2
• A Study of JNJ-64251330 in Participants With Familial Adenomatous PolyposisCompletedNCT05014360Phase 1
• Orelabrutinib in Combination With R2 Regimen for R/R CD20+ B-cell LymphomaStatus unknownNCT05014100Phase 2
• TQB2450 Solution for Injection (TQB2450)+Paclitaxel+Cisplatin ± Anlotinib in the Treatment of Esophageal Cancer.Status unknownNCT05013697Phase 2
• Efficacy and Safety of Neoadjuvant Surufatinib for Patients With Salivary Gland CarcinomasStatus unknownNCT05013515Not applicable
• Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell CancerActive, not recruitingNCT05012371Phase 2
• A Clinical Trial to Evaluate the Safety and Efficacy of AL2846 Capsules in Chinese Patients With Type I NeurofibromatosisTerminatedNCT05011019Phase 1/2
• Cryoablation Combined with Sintilimab Plus Lenvatinib in Patients with Advanced Intrahepatic CholangiocarcinomaCompletedNCT05010668Phase 2
• Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLCActive, not recruitingNCT05009836Phase 3
• Human Absorption, Distribution, Metabolism, and Excretion Study of [14C]AdavosertibTerminatedNCT05008913Phase 1
• Befotertinib and Icotinib in Treatment-naive Patients With Advanced EGFR-Mutant Lung CancerActive, not recruitingNCT05007938Phase 2
• ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic PhaseActive, not recruitingNCT05007873Phase 2
• Second-line Cabozantinib and Atezolizumab in Patients With Recurrent or Metastatic Esophageal Squamous Cell CarcinomaCompletedNCT05007613Phase 2
• Study on the Treatment of Differentiated Thyroid Carcinoma with AnlotinibActive, not recruitingNCT05007093Phase 2
• Bioequivalence Study of Baricitinib From Barcimiant 4 mg Film Coated Tablets (Horus Pharma, Egypt) and Olumiant 4 mg Film Coated Tablets (Eli Lilly Nederland B.V., The Netherlands)CompletedNCT05006768Phase 1
• Single and Multiple Ascending Dose Study of KN-002CompletedNCT05006521Phase 1
• A Phase II Trial of Camrelizumab Combined With Famitinib for Adjuvant Treatment of Stage II-IIIA NSCLC.Status unknownNCT05005468Phase 2
• Fruquintinib Combined With TAS-102 in the Treatment of Patients With Advanced Metastatic CRCStatus unknownNCT05004831Phase 2
• Acalabrutinib and Rituximab in Previously Untreated Mantle Cell LymphomaActive, not recruitingNCT05004064Phase 2
• Hepatic Arterial Infusion Combined With Lenvatinib and Camrelizumab for Unresectable Hepatocellular CarcinomaCompletedNCT05003700Phase 2
• Surufatinib Combined With Toripalimab and Chemotherapy in the Treatment of Non-Small Cell Lung CancerActive, not recruitingNCT05003037Phase 2
• Efficacy, Safety and Pharmacokinetics of Rilzabrutinib in Patients With Warm Autoimmune Hemolytic Anemia (wAIHA)Active, not recruitingNCT05002777Phase 2
• Anlotinib Plus Penpulimab as Second-line Treatment for Patients With Small Cell Lung Cancer After Failure of Platinum-based ChemotherapyCompletedNCT05001971Phase 2
• Chemotherapy Combined With Camrelizumab and Apatinib in First-line Treatment of ES-SCLCStatus unknownNCT05001412Phase 1
• A Prospective Clinical Study of Ruxolitinib and Etoposide Combined With DDGP Regimen (RUE-DDGP) in Induction Therapy of T/NK Cell Lymphoma-associated Hemophagocytic Syndrome.Status unknownNCT04999878Phase 4
• Study of Pembrolizumab Combined With Anlotinib in the First Line Therapy for R/M HNSCC With CPS≥1Status unknownNCT04999800Phase 2
• Axitinib + Ipilimumab in Advanced MelanomaActive, not recruitingNCT04996823Phase 2
• Surufatinib Combined With Chemotherapy Plus Toripalimab or Not in the Treatment of Small Cell Lung CancerStatus unknownNCT04996771Phase 1/2
• Toripalimab and Anlotinib Combination Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma After Failure of at Least One Line of Platinum-Based Chemotherapy (TORAL)CompletedNCT04996758Phase 2
• Pembrolizumab and Axitinib as Neoadjuvant Therapy for Locally Advanced Non-metastatic Clear Cell Renal Cell CarcinomaStatus unknownNCT04995016Phase 2
• Ningetinib in Advanced NSCLC Skipping Mutations With MET Exon 14 Skipping MutationsWithdrawnNCT04992858Phase 2
• TACE+Tilelizumab+Sorafenib in the Treatment of BCLC Stage C HCCStatus unknownNCT04992143Phase 2
• Fruquintinib Plus PD-1 Antibody in pMMR / MSS Locally Advanced Rectal Cancer (LARC) With High Immune ScoreStatus unknownNCT04989855Phase 2
• Pembrolizumab, Lenvatinib and Chemotherapy After TKIs in NSCLCStatus unknownNCT04989322Phase 2
• Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell CarcinomaCompletedNCT04987203Phase 3
• A Study Validating the Use of Candin as a Challenge Agent in Healthy Participants - Intervention Specific Appendix 3CompletedNCT04985955Phase 1
• To Evaluate the Efficacy of Durvalumab + Anlotinib in Terms of OS and PFS.Active, not recruitingNCT04985851Not applicable
• A Study of TAS2940 in Participants With Locally Advanced or Metastatic Solid Tumor CancerTerminatedNCT04982926Phase 1
• Treatment of EGFR-TKI for Residual Lesions of Multiple Synchronous Ground-glass OpacitiesStatus unknownNCT04982900Phase 2
• Camrelizumab Plus Amlotinib and Chemotherapy in the First-line Treatment of MelanomaStatus unknownNCT04979585Phase 2
• the Efficacy and Safety of Anlotinib Combined With Almonertinib in the First-line Treatment of Patients With Brain Metastases From EGFR Mutation-positive Non-small Cell Lung CancerStatus unknownNCT04978753Phase 2
• Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop StudyActive, not recruitingNCT04978584Phase 2
• Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)Active, not recruitingNCT04976634Phase 2
• A Study to Evaluate How Well Single and Multiple Doses of GLPG3667 Are Tolerated in Healthy, Adult SubjectsCompletedNCT04976270Phase 1
• ADCb (Anlotinib/Docetaxel/Carboplatin) as Neoadjuvant Therapy for Triple-Negative Breast CancerStatus unknownNCT04975451Phase 2
• First-line Treatment With Camrelizumab + Apatinib Versus Chemotherapy + Bevacizumab in Advanced Cervical CancerTerminatedNCT04974944Phase 2
• Osimertinib Combined With Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions Metastatic Non-Small Cell Lung CancerStatus unknownNCT04974879Phase 2
• Effect of Tofacitinib in Treating ANCA-associated VasculitisCompletedNCT04973033Not applicable
• A Phase 1b Study of ZN-c3 in Chinese SubjectsStatus unknownNCT04972422Phase 1
• Phase I BLASST-3 TrialWithdrawnNCT04972253Phase 1
• Drug-drug Interaction Study with GLPG4716 and Nintedanib and Pirfenidone in Healthy SubjectsCompletedNCT04971746Phase 1
• Anlotinib Plus Penpulimab (AK105) for Chemo-refractory Metastatic Colorectal Cancer:ALTER-C003Status unknownNCT04970914Phase 2
• Baricitinib in Hospitalized Covid-19 Patients With Diabetes MellitusWithdrawnNCT04970719Phase 3
• A Study of Furmonertinib Combined With Radiotherapy for Non-small Cell Lung Cancer With OligoprogressionStatus unknownNCT04970693Phase 2
• To Evaluate the Comparative Pharmacokinetics of Orally Administered EQ143 in Different Racial and Ethnic PopulationsCompletedNCT04969965Phase 1
• A Phase II Study of Sintilimab Combined With Anlotinib in Treatment of ED-SCLCStatus unknownNCT04967625Phase 2
• Trametinib Plus Anlotinib in Non-G12C KRAS-Mutant NSCLC PatientsCompletedNCT04967079Phase 1
• Phase 1b/2 Study of Futibatinib in Combination With Binimetinib in Patients With Advanced KRAS Mutant CancerTerminatedNCT04965818Phase 1
• A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)Active, not recruitingNCT04965493Phase 3
• A Study of Amivantamab and Lazertinib in People With Non-Small Cell Lung Cancer (NSCLC)CompletedNCT04965090Phase 2
• A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus K Drug in the Treatment of First-line Non-small Cell Lung Cancer(NSCLC)Status unknownNCT04964479Phase 3
• Pyrotinib and Vinorelbine Tartrate Capsules With or Without Inetetamab for First Line Treatment in Patients With Trastuzumab-resistant HER2-positive Advanced Breast CancerStatus unknownNCT04963595Phase 2
• Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal CancerActive, not recruitingNCT04963283Phase 2
• Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and ImmunotherapyActive, not recruitingNCT04963153Phase 1
• Tislelizumab Combined With Anlotinib and Chemotherapy (XELOX) in the Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (TALENT)CompletedNCT04963088Phase 1/2
• Acalabrutinib for GVHD Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplantation in Lymphomas and LeukemiaWithdrawnNCT04961801Phase 1/2
• Newly Diagnosed GlioblastomaActive, not recruitingNCT04959500Phase 2
• Phase Ib Study of FURMONERTINIB in Patients with NSCLC Having Exon 20 Insertion MutationWithdrawnNCT04958967Phase 1
• Surufatinib Combined With Toripalimab in Recurrent or Metastatic Nasopharyngeal CarcinomaStatus unknownNCT04955886Phase 2
• A Randomized Study to Investigate the Effect of Intravenous Imatinib on the Amount of Oxygen in the Lungs and Blood of Adults With COVID-19 Needing Mechanical Ventilation and Supportive Care.WithdrawnNCT04953052Phase 2
• Anlotinib or Penpulimab in Combination With RAI for DTCStatus unknownNCT04952493Phase 2
• Combination of Almonertinib and Concurrent Chemoradiotherapy in Unresectable Stage III NSCLCStatus unknownNCT04952168Phase 2
• A Phase III Study to Assess the Efficacy and Safety of Almonertinib Versus Platinum-based Chemotherapy as First-line Therapy in Patients With Locally Advanced or Metastatic NSCLC Harbouring Uncommon EGFR MutationStatus unknownNCT04951648Phase 3
• A Study of Camrelizumab Combined With Chemotherapy Sequential Camrelizumab Combined With Apatinib Treatment of Advanced NSCLCStatus unknownNCT04950400Not applicable
• A Study to Assess the Safety and Tolerability of Adavosertib for Patients With Advanced Solid TumoursTerminatedNCT04949425Phase 1
• A Study to Evaluate the Drug Levels of Deucravacitinib From Tablets After Oral Administration in Healthy ParticipantsCompletedNCT04949269Phase 1
• SHR1459 in Combination With YY-20394 in Recurrent and Refractory B-cell Non-Hodgkin's LymphomaStatus unknownNCT04948788Phase 2
• Camrelizumab Combined With Apatinib for Advanced Gastric or Esophagogastric AdenocarcinomaStatus unknownNCT04948125Phase 2
• The Combination of Fruquintinib, Tislelizumab and Stereotactic Ablative Radiotherapy in Metastatic Colorectal Cancer(RIFLE)Status unknownNCT04948034Phase 2
• Adjuvant Therapy With Anlotinib for HCCWithdrawnNCT04947371Phase 2
• Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study)Active, not recruitingNCT04947319Phase 2

← Tyrosine Kinase Inhibitors overview